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ABSTRAK
Gangguan fungsi ereksi adalah salah satu kesan sampingan metadon yang 
paling lazim. Gangguan ini menjejaskan lebih daripada separuh populasi 
pesakit metadon dari segi fungsi seksual mereka. Masalah ini dikaitkan dengan 
penurunan kualiti hidup yang ketara. Gangguan fungsi ereksi boleh menyebabkan 
masalah yang lebih besar jika tidak dirawat kerana pesakit mungkin memilih 
untuk menggunakan rawatan sendiri yang berbahaya seperti menyalahgunakan 
methamphetamine. Penggunaan dadah untuk mengatasi kesan sampingan 
metadon boleh menyebabkan gangguan penggunaan dadah ganda yang dapat 
mengganggu rawatan ketagihan dadah. Untuk mengatasi masalah ini, pengamal 
dan pesakit memainkan peranan yang penting dalam pengurusan gangguan fungsi 
ereksi. Kesedaran pesakit mengenai gangguan fungsi ereksi dan impaknya serta 
intervensi aktif oleh doktor untuk mengesan gangguan fungsi ereksi,  adalah penting 
untuk meningkatkan tingkat pengesanan dan pengurusan gangguan fungsi ereksi. 
Saringan gangguan fungsi ereksi yang kerap dan faktor risikonya akan membantu 
mengenalpasti pesakit yang menderita gangguan fungsi ereksi. Pelbagai pilihan 
rawatan seperti rawatan bupropion, trazodone dan banyak lagi tersedia untuk 
merawat gangguan fungsi ereksi yang akan diterokai lebih lanjut dalam kajian ini. 
Kata kunci: gangguan fungsi ereksi, kebergantungan opiat, metadon
ABSTRACT
Erectile dysfunction is one of the most common side effects of methadone affecting 
6Med & Health Jun 2020;15(1): 5-17 Fitri Fareez R. et al.
more than half of methadone patient population. The problem is associated with 
prominent reduced quality of life. Erectile dysfunction may perpetuate greater 
problem if left untreated as patients may opt to use harmful self-treatment such 
as abusing methamphetamine. This illicit drug use to overcome the side-effects 
of methadone may lead to polysubstance use disorder that further compromise 
addiction therapy. To overcome this issue, both practitioners and patients play a 
major role in the management of erectile dysfunction. Patient awareness regarding 
erectile dysfunction and its impact as well as doctor’s active intervention to detect 
erectile dysfunction, are essential to improve the detection rate and management of 
erectile dysfunction. Frequent screening of erectile dysfunction and its risk factors 
will help with the identification of patients suffering from erectile dysfunction. 
Multiple treatments options such as bupropion, trazodone and many more are 
available to treat erectile dysfunction which will be further explored in this review. 
Keywords: erectile dysfunction, methadone, opioid-related disorder 
with lower quality of life (Teoh et al. 
2017) particularly in patients with more 
severe ED (Lugoboni et al. 2017; Cheng 
et al. 2017). 
 Moreover, ED in MMT patients 
might facilitate the use of illicit 
drugs such as methamphetamine. 
Wang et al. (2015) found the use of 
methamphetamine in MMT patients 
was significantly associated with a 
longer and higher dose of methadone. 
Radfar et al. 2016 reported that  SD as 
one of the reasons that motivate the 
use of this methamphetamine to self-
treat the side effects of MMT (Radfar et 
al. 2016).
 Despite the high prevalence of ED 
and its unfavorable effects on MMT 
patients, the management of this issue 
is still inadequate. Both patients and 
practitioners factors contributes to the 
lack of ED management. The attitude 
of patients regarding ED problem 
would determine their health-seeking 
behaviour. In the general population, 
INTRODUCTION
Methadone has been widely used for 
the treatment of opioid use disorder. 
It has been proven to be effective 
in reducing heroin use, craving, 
criminality and transmission of 
infectious diseases (Joseph et al. 2000). 
However, methadone treatment also 
causes significant side effects related 
to opioid such as sexual dysfunction 
(SD), sleep disorder and weight gain 
(Parvaresh et al. 2015). 
 Erectile dysfunction (ED) is one 
common adverse effects of opioids, 
including methadone. Zhao et al. 
(2017) in a meta-analysis study 
reported nearly two-fold increased risk 
of ED in opioid-dependent patients. 
The risk of ED was 82% greater in 
patient on methadone maintenance 
treatment (MMT) than those who 
were not on MMT (Zhao et al. 2017). 
ED in MMT population deserve 
significant attention as it is associated 
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the rate of ED consultation with the 
doctors varies, ranging from 10.5-25% 
(Giuliano et al. 2002; Ab Rahman et al. 
2011). The reasons for patients’ refusal 
to refer their ED issue for medical 
attention include the perception of ED 
as a normal ageing consequence or due 
to other medical problem (Ab Rahman 
et al. 2011). In MMT population, 
only 18.5% of patients sought for 
medical treatment. The main barriers 
for seeking medical treatment in this 
specific population are the perception 
that ED is not a serious condition and 
hesitancy (Ramli et al. 2019). In terms 
of practitioners aspect, engagement 
of practitioners in sexual-related topic 
and proper documentation are crucial. 
A Global Study of Sexual Attitudes 
and Behaviors (GSSAB) demonstrated 
that 15% or less of men had ever been 
asked regarding their sexual problem 
in the past three years across all 
regions in the world (Moreira Jr et al. 
2005). In total, 48% of men in GSSAB 
highlighted doctors should routinely 
inquire patients regarding their sexual 
function. Moreover, Read et al. (1997) 
had reported the absent of SD-related 
notes in 25 people with the most severe 
SD.  These data show the lack of interest 
or awareness of doctors regarding the 
sexual health-related topic.   
 Awareness and knowledges of both 
patients and practitioners regarding 
ED and its available treatment options 
are important so that, ED can be 
managed efficiently in this specific 
population. This review aims to 
increase knowledge and awareness 
of medical practitioners involve in 
methadone facilities service with focus 
on the ED and methadone, prevalence, 
pathophysiology, risk factors, screening 
tools and current treatment options 
available. We propose an algorithm 
for ED management in the MMT 
population.
Erectile Dysfunction 
ED is defined as ‘the inability to achieve 
and maintain a penile erection adequate 
for satisfactory sexual intercourse’ 
(NIH 1993). The prevalence of ED in 
the general population varies, ranging 
from 18.4% to 69.5% (Ab Rahman et 
al. 2011; Rosen et al. 2004; Selvin et al. 
2007). The physiology of erection lies 
on both neurogenic and vasculogenic 
factors. Erection needs smooth muscle 
relaxation of both corpus cavernosa 
and penile arteries. Relaxation of these 
structures is regulated by both local 
and systemic factors and leads to the 
filling of intracavernosal structures and 
blood engorgement with subsequent 
erection (Andersson & Wagner 1995).  
Interruption of any factors related to 
this hemodynamic process would 
result in ED.  
 There are various factors that can 
increase the risk of ED, one of which is 
age. Increasing age is associated with 
higher risk of ED as well as its severity 
as demonstrated in multiple studies 
(Akkus et al. 2002; Selvin et al. 2007). 
Certain diseases are also related to 
increased risk of ED such as diabetes, 
hypertension, heart disease and 
dyslipidemia (Akkus et al. 2002; Rosen 
et al. 2004; Selvin et al. 2007; Wei et 
al. 1994). Wei et al. (1994) found that 
person with higher total cholesterol, 
higher low-density lipoprotein or lower 
high-density lipoprotein has higher 
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risk of ED. Psychogenic causes such as 
depression and anxiety are another risk 
factors for ED (Akkus et al. 2002; Rosen 
et al. 2004). Sedentary lifestyle such as 
lack of exercise can also contribute to 
ED (Selvin et al. 2007).
Methadone
Methadone  has similar  
pharmacological properties to 
morphine and is categorized into 
the μ opioid receptor (MOR) agonist 
(Schumacher et al. 2015; Yaksh 
& Wallace 2017). The affinity of 
methadone is more prominent towards 
μ receptor whilst affinity towards ĸ and 
δ receptors is low (Kristensen et al. 
1994). Moreover, methadone has the 
capability of inhibiting NMDA and 
monoaminergic reuptake transporters 
(Schumacher et al. 2015). 
 Methadone is well absorbed 
orally and the peak concentration is 
achieved in 2.5-4 hours (Lugo et al. 
2005; Yaksh & Wallace 2017). The 
bioavailability ranged between 60-
70% and could be affected by pH, 
gastric motility as well as gut perfusion 
(Lugo et al. 2005). Methadone is widely 
distributed particularly in certain tissue 
such as brain (Lugo et al. 2005). The 
half-life of methadone ranges from 
15-40 hours (Yaksh & Wallace 2017). 
Methadone is highly protein-bound 
with the major portion being bound 
to alpha-1-acid glycoprotein (Lugo et 
al. 2005). Methadone is metabolized 
by the liver into two major inactive 
metabolites, 2-ethylidine-1,5-dimethyl- 
3,3-diphenylpyrrolidine (EDDP) and 
2-ethyl-5-methyl-3,3-diphenyl-1-
pyrroline (EMDP) by CYP3A4 and 
CYP2B6 (Lugo et al. 2005; Schumacher 
et al. 2015). Both renal and faeces are 
the route of methadone elimination. 
 Methadone is indicated for the 
treatment of opioid use disorder. It is 
suitable to be used as replacement 
therapy for other opioids such as 
morphine due to its characteristics 
such as longer half-life and availability 
in oral form with acceptable 
bioavailability. The use of methadone 
as replacement therapy for opioids 
had demonstrated favourable outcome 
in multiple studies. In a meta-analysis 
study, methadone was shown to 
retain patients in MMT programme 
as well as reduce illicit heroin use as 
compared to non-opioids replacement 
therapy (Mattick et al. 2009). Another 
meta-analysis study demonstrated the 
effectiveness of MMT for reduction of 
illicit drug use, criminal-related to drug 
and HIV risk behaviors (Marsch 1998).
Despite the proven evidence of 
methadone effectiveness, methadone 
is associated with many adverse 
effects. In this review article, we focus 
on methadone induced ED.
Prevalence of Erectile Dysfunction 
in Methadone Maintenance 
Treatment Patients
The prevalence of ED among MMT 
patients varies, ranging from 53-87.4% 
(Hallinan et al. 2008; Nik Jaafar et al. 
2013; Teoh et al. 2017; Zhang et al. 
2014). Nik Jaafar et al. (2013) found 
that mild ED was the most prevalent 
group in MMT patient with prevalence 
of 36.1%. Teoh et al. (2017) reported 
the most prevalent group was mild-
moderate ED (30.4%). Hallinan et al. 
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(2008) reported higher prevalence 
in men with partners above 40s in 
comparison to under 40s (65% vs 
45,5%). Cheng et al. (2017) reported a  
higher prevalence of patients above 40 
in both no-mild ED group (79.6%) and 
moderate-severe ED group (80%). 
Pathophysiology of Methadone-
Induced Erectile Dysfunction
 
Reduction of serum testosterone level 
is one of the possible mechanisms for 
ED in the opioid user which include 
methadone patients and this might be 
related to the effect of methadone on 
hypothalamic-pituitary-gonadal (HPG) 
axis (Figure 1). Singh et al. (1982) had 
demonstrated the gonadotropins-
releasing hormone (GnRH) from 
hypothalamus was inhibited following 
administration of methadone due 
to blockade of dopamine pathway 
resulting in pronounced decreased 
in testosterone levels in the blood, 
15 minutes post methadone 
administration.
 A study conducted in rats showed 
pronounced effects of methadone 
on serum testosterone levels and 
secondary male sex organs (Cicero et 
al. 1976). This study showed significant 
reduction in serum testosterone 
levels and weight of seminal vesicles 
Figure 1: Pathophysiology of opioid-induced sexual dysfunction. Red line indicate the inhibition of 
opioid on organs. The consequence of opioid inhibition on these organs is low levels of testosterone. 
Low levels of testosterone may have negative impact on sexual desire and lead to structural and 
functional alteration of male secondary sexual organ such as seminal vesicles. GRH: gonadotropin-
releasing hormone, LH: Luteinizing hormone.
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and prostate glands. The effects 
can be explained by the action of 
opioids on hypothalamus or pituitary 
gland, resulting in decreased level 
of luteinizing hormones (LH) and 
leading to a secondary reduction of 
testosterone level (Cicero et al. 1976).
 Ghowsi & Yousofvand (2015) found 
similar finding in term of testosterone 
level. They found significantly lower 
testosterone level in morphine as 
well as morphine+methadone treated 
group compared to the control group. 
However, LH level was not significantly 
lowered in morphine+methadone 
group compared to control group. 
Similarly, follicle-stimulating hormone 
(FSH) level was found not to be 
significantly different. In terms of the 
effect on secondary sexual organs, 
only seminal vesicles fluid volume 
was noted to be significantly reduced 
in morphine+methadone group. 
Moreover, Adams et al. (1993) reported 
that opioid has direct suppressive 
effects on testosterone secretion via 
opioid receptors found in the testes. 
 The reduction of plasma testosterone 
level might lead to ED. Gerra et al. 
(2016) had demonstrated a significant 
association between lower testosterone 
level with higher SD. Bawor et al. (2015) 
found significantly lower testosterone 
levels in men on MMT and negative 
association between methadone 
dose and testosterone level in a case-
control study. A meta-analysis study 
on randomised controlled trial found 
a significant effect of low testosterone 
levels on diminished libido (Bolona 
et al. 2007). This indicates lower 
testosterone level leads to SD by 
decreasing libido. Figure 1 illustrates 
the pathophysiology of methadone-
induced ED. 
Risk Factors of Methadone-Induced 
Erectile Dysfunction
Multiple factors are associated with 
ED in this population. One of the 
common risk factors is age. Zhang et 
al. (2014) found significant association 
between age and SD in heroin-
dependent patients after initiation of 
MMT in three domains; ED, inability 
to orgasm and lack of sexual desire. 
Nik Jaafar et al. (2013) and Cioe et al. 
(2010) demonstrated age was the only 
significant risk factor for ED among 
MMT patients. On contrary, Cheng 
et al. (2017) showed no considerable 
age difference between no-to-mild ED 
group and moderate-severe ED group.
 Depression is another risk factor for 
ED in MMT patients. Quaglio et al. 
(2008) showed MMT patients had a 
significantly higher risk of depression 
compared to buprenorphine 
maintenance therapy (BMT) group 
with the odds ratio (OR) of 1.06 
(95% CI=1.03-1.09). Teoh et al. (2017) 
demonstrated that depression was 
significantly associated with ED 
with the OR of 3.98 (95% CI=1.52-
10.40). Lugoboni et al. (2017) found 
depression was significantly associated 
with ED with the OR of 2.25 (CI=1.43-
3.53). Depression was also found to be 
substantially correlated with severity 
of ED (Lugoboni et al. 2017). Another 
study found no significant association 
between depression and ED (Nik Jaafar 
et al. 2013). 
 The dose and duration of methadone 
treatments are the other risk factors 
associated with ED in MMT patients. 
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The results from various studies 
yielded either positive or negative 
significant association as well as no 
significant correlation. Some studies 
demonstrated higher methadone 
dose is associated with worse SD. A 
meta-analysis study conducted found 
a significant positive association 
between methadone dose and ED in 
MMT patients compared to BMT group 
(Yee et al. 2014). Similarly, Cheng et al. 
(2017) found a significant association 
between higher methadone dose 
and increased severity of ED. On the 
other hand, some studies showed a 
positive impact of MMT on sexual 
function. Babakhanian et al. (2012) 
found a significant improvement of 
erectile function domain score after 
6 months MMT. Zhang et al. (2014) 
reported pronounced improvement in 
all domains of IIEF-15 after MMT. The 
improvement in sexual function in both 
studies above compare before and after 
MMT treatment in heroin-dependent 
patients that conclude SD is worse 
with heroin than methadone. Other 
studies found no significant association 
between dose of methadone treatment 
and ED (Brown et al. 2005; Nik Jaafar 
et al. 2013).
 Abnormal hormone level is also 
associated with ED. Hallinan et al. 
(2009) found significantly lower total 
testosterone, free testosterone and LH 
level in MMT patients compared to 
age-matched reference group as well 
as BMT group. FSH and prolactin levels 
were not significantly lower compared 
to other groups. Similarly, Gerra et al. 
(2016) found that lower testosterone 
level was significantly associated 
with higher SD and no significant 
association found between prolactin 
level and SD. On the contrary, Cioe 
et al. (2010) showed no significant 
difference in total testosterone level 
between ED and non-ED group in 
BMT group.  
Screening for Erectile Dysfunction
International index of erectile function 
(IIEF) is one of the commonest 
diagnostic tools for ED. IIEF has been 
validated in multiple languages and is 
available in full or simplified version. 
IIEF discriminate between ED and non-
ED as well as classify the severity of ED. 
The cut-off point in each version might 
be similar or different, depending on 
the version. IIEF is introduced by Rosen 
et al. (1997) and consists of 15 items 
which include five domains (sexual 
desire, erectile function, orgasmic 
function, intercourse satisfaction 
and overall satisfaction). The internal 
consistencies (Cronbach’s alpha) for 
each of five domains and overall score 
were >0.73 and >0.91, respectively. 
The test-retest repeatability value 
swere 0.64-0.84. 
 IIEF is also available in a simplified 
version. IIEF-5 is one of the versions 
with high sensitivity (0.98) and 
specificity (0.88) at cut-off point of 
21 (Rosen et al. 1999). The estimated 
area under receiver operating 
characteristics (ROC) curve was 0.97 
and the estimated kappa coefficient 
was 0.85 (Rosen et al. 1999).  Based 
on IIEF-5, ED is classified into no ED 
(score 22-25), mild (score 17-21), mild-
moderate (score 12-16), moderate 
(score 8-11) and severe (score 5-7) 
(Rosen et al. 1999). The other versions 
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of IIEF-5 have a cut-off point of 17 such 
as Korean version and Malay version 
(Ahn et al. 2001; Lim et al. 2003). 
 Cappelleri et al. (1999) had 
produced another version of IIEF 
based on erectile function domains 
of IIEF-15. This questionnaire consists 
of six items and has a cut-off point 
of 25 with the sensitivity of 0.97 and 
specificity of 0.88. The weighted 
kappa of this instrument is 0.80. ED 
severity is classified as no ED (score 
26-30), mild (22-25), mild to moderate 
(17-21), moderate (11-16) and severe 
(score 6-10). 
Management for Methadone-
Induced Erectile Dysfunction
Algorithm for management of erectile 
dysfunction in methadone patients
All patients who are enrolled in 
MMT program should be screened 
for ED using a questionnaire such as 
IIEF. The propose algorithm is shown 
in Figure 2. Patient with ED should 
be further evaluated for current or 
history of illness or disease and other 
medications used concurrently. The 
history taking is important as certain 
diseases such as hepatitis (Kim et 
al. 2015), hypertension and diabetes 
are associated with higher risk of ED 
(Rosen et al. 2004). Medication such 
as antihypertensive (Blumentals et al. 
2003) and antidepressant (Kupelian et 
al. 2013) are potential risk for ED. Patient 
sexual history with partner should be 
Figure 2: Algorithm for management of erectile dysfunction in methadone maintenance treatment 
patients
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obtained as partner sexual-related 
problem may impair sexual activity 
(Seen Heng et al. 2013). Depression 
assessment could be considered as 
depression is an independent risk factor 
in MMT patient with ED. The risk of ED 
in MMT patients is four times higher 
than those without depression (Teoh et 
al. 2017). Physical examination such as 
body mass index and blood pressure 
can be performed to screen for risk 
factors associated with ED. Blood 
investigations such as lipid profile 
(Wei et al.1994) and glucose level or 
glycemic index (Ugwu et al. 2016) 
should be carried out to determine 
the possible condition associated 
ED. Hormonal assessment such as 
testosterone level should be conducted 
to see any hormonal abnormalities 
as opioids including methadone is 
a known substance associated with 
testosterone suppression (Bawor et al. 
2015). Underlying conditions such as 
hypertension, diabetes or depression 
should be treated accordingly and 
referral to the specialist should 
be considered for concurrent 
management of underlying disease and 
ED. Physician should carefully select 
the medication with less potential to 
cause ED. Pharmacotherapy such as 
bupropion (Tatari et al. 2013; Yee et al. 
2018) and trazodone (Tatari et al. 2013) 
can be considered for management 
of ED in MMT patients. Partners with 
sexual problem should be advised 
to get assessment and treatment 
as improvement of partner may 
contribute to better sexual experience 
and less dysfunction (Seen Heng et 
al. 2013). Periodic assessment of ED is 
needed for patients with or without ED 
to assess ED occurrence and response 
of ED treatment. 
Pharmacological intervention
There are multiple treatment 
modalities for the management of ED 
in MMT patients. Treatments include 
altering methadone dose, switching 
to buprenorphine, testosterone 
replacement therapy or treatment 
with bupropion, trazodone or rosa 
damascena oil. 
 Methadone dose may be reduced to 
deal with SD side effect. This approach 
is supported by a meta-analysis study 
that showed higher methadone dose 
is associated with a higher SD level 
(Yee et al. 2014). Cheng et al. (2017) 
also found a significant association 
between higher methadone dose 
and more severe ED. However, 
this approach might reduce the 
effectiveness of methadone treatment 
for opioid disorder and promote illicit 
drug use  such as methamphetamine.  
 Buprenorphine may be considered 
as an alternative treatment for those 
patients with opioid use disorder on 
MMT who are suffering from ED. This 
recommendation is supported by a 
study that demonstrated buprenorphine 
group had lower SD in libido and 
potency aspects than methadone 
group (Bliesener et al. 2005). Another 
study found a significant difference in 
IIEF score in MMT group compared to 
BMT group that indicates more severe 
ED in the former group (Hallinan et 
al. 2008). Buprenorphine may be 
used as an alternative to methadone 
as it is effective in suppressing illicit 
opioid use and retaining patient in 
replacement therapy. The effectiveness 
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of buprenorphine is comparable to 
methadone when used as a fixed-
dose with medium to high range dose 
(Mattick et al. 2014). 
 Testosterone replacement therapy 
may also benefit MMT patient with ED. 
Blick et al. (2012) showed significant 
improvement of sexual function in 
opioid users patients in 12  months 
treatment with 1% testosterone gel. This 
result was comparable to those non-
opioid users with SD. The testosterone 
level was significantly increased after 
one-month treatment but not at 6 
and 12 months probably due to less 
number of samples collected (n=6-9). 
 Another treatment option 
is bupropion. Bupropion is an 
antidepressant. Pharmacological 
properties of this medication lie on 
its ability to increase the level of 
dopamine and noradrenaline blockade 
effects centrally via multiple signaling 
pathway such as dopaminergic and 
nitric oxide signaling pathway (Dhir 
& Kulkarni 2007). A result from 
randomised, placebo-controlled trial 
found a significant improvement in 
several domains of IIEF-15 (erectile 
function, sexual desire) as well as 
in Sexual Desire Inventory-2 Malay 
Version (SDI-2-BM) (Yee et al. 2018). 
Salehi et al. (2015) also reported 
improvement in SD after eight weeks 
of treatment with bupropion but not for 
depression. Tatari et al. (2013) showed 
significant improvement of SD after 
6-week treatment with 100 mg daily 
bupropion in MMT patient with ED.
 Trazodone is an antidepressant 
that might have beneficial therapeutic 
effects for the treatment of ED in this 
population. Trazodone has the ability to 
block both serotonin and noradrenaline 
that explains its therapeutic action 
as an antidepressant (Brogden et al. 
1981). The antagonism of both alpha-1 
and -2 adrenergic receptors might 
explain trazodone effects on erection 
(Krege et al. 2000). A meta-analysis 
study conducted showed a beneficial 
effect of trazodone in the treatment 
of psychogenic-related ED (Fink et al. 
2003). However, data regarding the 
use of trazodone in MMT group with 
ED is limited. Tatari et al. (2010) had 
shown a significant improvement in 
MMT patients with ED treated with 
100 mg daily trazodone after eight 
weeks of treatment.  Further study may 
need to be done with a larger sample 
size to investigate the role of trazodone 
for methadone-induced ED treatment. 
 Rosa Damascena oil is an 
alternative treatment for ED in this 
population. This plant can be found 
predominantly in certain countries 
such as Iran and Turkey (Tabaei-
Aghdaei et al. 2007). Pharmacological 
effects of Rosa Damascena flowers 
include antioxidant, antibacterial, 
antidiabetic, hypnotics and many 
more (Boskabady et al. 2011). A 
double-blind randomised-controlled 
trial had proven the use of this for the 
treatment of ED. In this study, 2 ml of 
Rosa Damascena oil or placebo were 
administered via drop to the patients 
for eight weeks. Results showed a 
significant improvement of SD as well 
as testosterone level in Rosa treated 
group (Farnia et al. 2017).   
CONCLUSION
ED is a common side effect of 
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methadone treatment that needs 
to be addressed. Assessment with 
a simple tool such as IIEF-5 helps 
in ED detection. Practitioners who 
deal with MMT patients should 
actively screen for ED and provide 
appropriate management. Testosterone 
replacement therapy, bupropion, 
trazodone and Rosa Damascena oil 
treatment show promising results from 
randomized controlled trials. 
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